NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Deagreez/iStock via Getty Images Just over 4 months have passed since my last article, "Is Novo Nordisk Immune to President Trump's Drug Price Plans." What was it about? In it, I presented an analysis of the clinical development program for ...

Core Insights - Berger Montague PC is investigating claims against Novo Nordisk A/S under federal securities laws following a class action lawsuit filed against the company [1][2]. Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Investor Information - Investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2].

Secretary of Health and Human Services Robert F. Kennedy Jr.The Associated PressTylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.Tylenol may be only the beginning.For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and ...

Core Insights - Eli Lilly's orforglipron shows superiority in lowering A1C levels compared to Novo Nordisk's oral semaglutide in a head-to-head trial for type 2 diabetes treatment [2][3] - The reported weight loss results for orforglipron may not be directly comparable to those of oral semaglutide due to differences in dosage used in trials [4][6] - The trial results should not be interpreted as a definitive victory for Eli Lilly in the obesity treatment market, which remains a more lucrative segment [7] Eli Lilly's Trial Data - The head-to-head trial aimed at reducing A1C levels, with orforglipron achieving a 2.2% reduction at 36mg compared to a 1.4% reduction for oral semaglutide at 14mg [3] - Eli Lilly reported an average weight loss of 9.2% with orforglipron at the highest dosage, while oral semaglutide at 14mg resulted in a 5.3% reduction [4] - Novo Nordisk is testing oral semaglutide at a higher dosage of 25mg, which has shown an average weight reduction of 16.6% in its trials [6] Implications for Investors - The positive trial results for Eli Lilly in type 2 diabetes treatment do not necessarily indicate that orforglipron will outperform oral semaglutide in the obesity indication, which is a more profitable market [7]

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per share and is deeply undervalued. While they haven't been doing all that well of late, over the long run, they could generate some terrific returns given their low valuations.Here's why you'll want to consi ...

欧洲制药股在早盘交易中下跌，诺和诺德、诺华制药、阿斯利康在德国Tradegate交易平台下跌 1.7%-2%。 （文章来源：第一财经） ...

每经AI快讯，9月26日，诺和诺德在Tradegate交易平台上下跌3%。 ...

Core Insights - Amylin, a previously overlooked target, is emerging as a significant player in the multi-billion dollar weight loss market, particularly with the recent data from Novo Nordisk's cagrilintide and its combination with semaglutide showing promising weight loss results [1][2][3] Group 1: Clinical Developments - Novo Nordisk's cagrilintide achieved an average weight loss of 11.8% after 68 weeks of treatment in the REDEFINE 1 study [1] - The combination formulation CagriSema, which includes cagrilintide and semaglutide, demonstrated an average weight loss of 20.4%, significantly outperforming monotherapy [1][9] - Novo Nordisk has registered a Phase 2 clinical trial for NNC0662-0419, a GLP-1/GIP/Amylin triple agonist [1] Group 2: Industry Movements - Pfizer announced a $4.9 billion cash acquisition of Metsera to strengthen its weight loss pipeline, leading to a significant surge in Metsera's stock price [1] - Major pharmaceutical companies like Roche, AstraZeneca, Eli Lilly, and AbbVie are increasingly investing in Amylin through collaborations and acquisitions [2][11] Group 3: Mechanism and Competitive Advantage - Amylin is not a new target; it was discovered in 1987 but faced challenges in earlier formulations due to short half-lives and side effects [3][4] - New generation Amylin analogs have significantly improved half-lives, allowing for less frequent dosing, which enhances patient compliance [5][10] - Amylin's mechanism offers complementary effects to GLP-1, potentially leading to better patient outcomes through combined therapies [8][9] Group 4: Future Directions - The industry consensus is shifting towards collaborative strategies rather than isolated competition, with companies exploring combinations of Amylin and GLP-1 for enhanced efficacy [12][16] - Innovations in drug delivery systems, such as long-acting formulations and oral delivery methods, are being prioritized to improve patient adherence and treatment outcomes [15][16]

Market Movements - Oracle shares fell over 5% while Tesla dropped more than 4%, resulting in a market value loss of $64.5 billion (approximately 460.2 billion RMB) in one night [1] - Intel surged nearly 9% as it engaged in discussions with Apple regarding potential investments to strengthen its business foundation [3] - Cryptocurrency and weight-loss stocks saw significant declines, with Hut 8 down over 7% and Circle down over 5% [5] Economic Indicators - The U.S. GDP for Q2 was revised to an annualized quarter-on-quarter growth of 3.8%, exceeding expectations of 3.3% [8] - The core Personal Consumption Expenditures (PCE) price index for Q2 was reported at 2.6%, higher than the anticipated 2.5% [8] - Analysts noted that the strong GDP report indicates persistent inflation pressures, which may limit the Federal Reserve's future rate cuts [9] Federal Reserve Outlook - The Federal Reserve's recent rate cut of 25 basis points may not significantly alter its expected path for future cuts due to ongoing inflation concerns [9] - The probability of maintaining rates in October is 14.5%, while the likelihood of a 25 basis point cut is 85.5% [10]